These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19119105)

  • 1. The EuroSCAR study: cannot agree with the conclusions.
    Pehr K
    J Am Acad Dermatol; 2008 Nov; 59(5):898-9; author reply 899-900. PubMed ID: 19119105
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study.
    Schneck J; Fagot JP; Sekula P; Sassolas B; Roujeau JC; Mockenhaupt M
    J Am Acad Dermatol; 2008 Jan; 58(1):33-40. PubMed ID: 17919775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of Stevens Johnson syndrome and toxic epidermal necrolysis treated with corticosteroids.
    Rijal A; Agrawal S
    Indian J Dermatol Venereol Leprol; 2009; 75(6):613-4. PubMed ID: 19915248
    [No Abstract]   [Full Text] [Related]  

  • 4. IVIG for the treatment of toxic epidermal necrolysis.
    Mittmann N; Chan BC; Knowles S; Shear NH
    Skin Therapy Lett; 2007 Feb; 12(1):7-9. PubMed ID: 17361314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.
    Arca E; Köse O; Erbil AH; Nişanci M; Akar A; Gür AR
    Pediatr Dermatol; 2005; 22(4):317-20. PubMed ID: 16060867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe cutaneous adverse drug reactions: who should treat, where and how?: Facts and controversies.
    Wolf R; Davidovici B
    Clin Dermatol; 2010; 28(3):344-8. PubMed ID: 20541690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases].
    Molgó M; Carreño N; Hoyos-Bachiloglu R; Andresen M; González S
    Rev Med Chil; 2009 Mar; 137(3):383-9. PubMed ID: 19621180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Stevens-Johnson syndrome and toxic epidermal necrolysis; therapy policy in these life-threatening illnesses. Netherlands Work Group Toxic Epidermal Necrolysis].
    van der Meer JB
    Ned Tijdschr Geneeskd; 1996 Jul; 140(30):1538-43. PubMed ID: 8765761
    [No Abstract]   [Full Text] [Related]  

  • 10. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
    Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
    Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An application of propensity score methods to estimate the treatment effect of corticosteroids in patients with severe cutaneous adverse reactions.
    Sekula P; Caputo A; Dunant A; Roujeau JC; Mockenhaupt M; Sidoroff A; Schumacher M
    Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):10-8. PubMed ID: 19795365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asboe-Hansen sign in toxic epidermal necrolysis.
    Dowling JR; Anderson KL; Huang WW
    Cutis; 2019 Apr; 103(4):E6-E8. PubMed ID: 31116821
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravenous immunoglobulin therapy for Stevens-Johnson syndrome.
    Brett AS; Philips D; Lynn AW
    South Med J; 2001 Mar; 94(3):342-3. PubMed ID: 11284525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of high dose intravenous immunoglobulins in dermatology].
    Mockenhaupt M; Roujeau JC
    J Dtsch Dermatol Ges; 2010 May; 8(5):386-7; author reply 387-9. PubMed ID: 20537010
    [No Abstract]   [Full Text] [Related]  

  • 15. [On erythema exsudativum multiforme and the Lyell syndrome].
    Wilk F; Scholz R
    Wien Med Wochenschr; 1968 Aug; 118(33):663-8. PubMed ID: 5680493
    [No Abstract]   [Full Text] [Related]  

  • 16. Pentoxyfylline in toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Sanclemente G; De la Roche CA; Escobar CE; Falabella R
    Int J Dermatol; 1999 Nov; 38(11):878-9. PubMed ID: 10583942
    [No Abstract]   [Full Text] [Related]  

  • 17. Toxic epidermal necrolysis in HIV-infected patients: are intravenous immunoglobulins really necessary in this subgroup?
    Mancinelli MC; Feola H; Alessandro AM; Verea MA
    Int J STD AIDS; 2021 Feb; 32(2):202-204. PubMed ID: 33308088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Fromowitz JS; Ramos-Caro FA; Flowers FP;
    Int J Dermatol; 2007 Oct; 46(10):1092-4. PubMed ID: 17910723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic and local management at the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications.
    Sotozono C; Ueta M; Kinoshita S
    Am J Ophthalmol; 2010 Feb; 149(2):354; author reply 355. PubMed ID: 20103059
    [No Abstract]   [Full Text] [Related]  

  • 20. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Yeung CK; Lam LK; Chan HH
    Clin Exp Dermatol; 2005 Sep; 30(5):600-2. PubMed ID: 16045716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.